741234
Last Update Posted: 2012-04-23
Recruiting has ended
All Genders accepted | 18 Years + |
85 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in cohorts of patients with advanced hematologic malignancies. Arm C will assess the safety and tolerability of SB939 in combination with standard azacitidine therapy.
Eligibility
Relevant conditions:
Solid Tumors
Hematologic Malignancies
Myelodysplastic Syndrome
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov